Demand- Versus Supply-Side Policies in Market Penetration of Biosimilars: Which is More Effective? [0.03%]
需求方与供给方政策在生物仿制药市场渗透方面的有效性比较如何？
Gyeongseon Shin,Heejin Han,Gyeyoung Choi et al.
Gyeongseon Shin et al.
Objective: To evaluate the impact of demand- and supply-side policies on the biosimilar market penetration and identify effective strategies for promoting biosimilar uptake in eight high-income countries. ...
Malte Lenders,Elise Raphaela Menke,Eva Brand
Malte Lenders
Fabry disease is a rare but life-threatening, X-linked, inherited lysosomal storage disorder in which globotriaosylceramide is insufficiently metabolized because of reduced α-galactosidase A activity. Cellular globotriaosylceramide accumul...
Interrogation of Structure-Activity Relationships in Charge Variants of Therapeutic IgG2s Enabled by Free-Flow Isoelectric Focusing Fractionation [0.03%]
基于自由流等电聚焦分离的治疗性IgG2电荷异质体结构活性关系研究
Lingyu Wang,Yajun Zeng,Wenyuan Gao et al.
Lingyu Wang et al.
Background: Recombinant immunoglobulin G2 (IgG2) antibodies are effective neutralization agents or antagonists with high medical value because of their high specificity, long half-life, and absent effector functions. Duri...
Switching from Adalimumab Reference Product to and Among Adalimumab Biosimilars Outside the USA: Insights for US Clinicians [0.03%]
从adalimumab原研药转换为和在不同adalimumab生物类似药之间切换（在美国以外的地区）：给美国临床医师的启示
John R P Tesser,Aline Charabaty,Adelaide A Hebert
John R P Tesser
Ten adalimumab biosimilars have been introduced in the United States (USA) since 2023, while adalimumab biosimilars have been available for several years in other countries. These experiences of biosimilar uptake outside the USA can inform ...
Understanding IgM Structure and Biology to Engineer New Antibody Therapeutics [0.03%]
利用 IgM 结构和生物学特性来设计新型抗体药物
Johannes Buchner,Roberto Sitia,Hristo L Svilenov
Johannes Buchner
Immunoglobulin M (IgM) antibodies are an essential and conserved part of adaptive immunity. IgMs assemble into pentamers and hexamers that bind to antigens with high avidity. Pentamers incorporate a small protein called J-chain (JC) that is...
Real-World Evidence on the Effectiveness and Safety of Spesolimab in the Treatment of Generalized Pustular Psoriasis Flares: A Case Series [0.03%]
关于斯泼索利单抗治疗泛发性脓疱型银屑病加重的真实世界有效性和安全性的病例系列研究
Martim Luz,M Ribeiro,M Alpalhão et al.
Martim Luz et al.
The Fomivirsen, Patisiran, and Givosiran Odyssey: How the Success Stories May Pave the Way for Future Clinical Translation of Nucleic Acid Drugs [0.03%]
Fomivirsen、Patisiran和Givosiran的历程：成功案例如何为核酸药物的未来临床转化铺平道路
Mona Mansouri,Kimia Mansouri,Zahra Taheri et al.
Mona Mansouri et al.
Over the past 25 years, the approval of several nucleic acid-based drugs by the US Food and Drug Administration (FDA) has marked a significant milestone, establishing nucleic acid drugs as a viable therapeutic modality. These groundbreaking...
Translational Investigation of CM326 from Preclinical Studies to Randomized Phase I Clinical Trials in Healthy Adults [0.03%]
从临床前研究到健康成人中随机I期临床试验的CM326转化研究
Yujing Di,Ling Yang,Jianfei Zhou et al.
Yujing Di et al.
Background: Thymic stromal lymphopoietin (TSLP) plays a pivotal role in immune responses. CM326 is a humanized monoclonal antibody targeting TSLP. Objecti...
Frequency of Biological Drug Use in Older Patients with Immune-Mediated Inflammatory Diseases: Results from the Large-Scale Italian VALORE Distributed Database Network [0.03%]
意大利VALORE分布式数据库网络免疫介导性炎症疾病老年患者生物制剂使用频率分析
Federica Soardo,Andrea Spini,Giorgia Pellegrini et al.
Federica Soardo et al.
Background: Limited real-world data on biological drug use in older patients with immune-mediated inflammatory diseases (IMIDs) exist despite these drugs carrying serious risks in this population. ...
First-in-Human Study on Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Escalating Doses of HEC88473, a Novel Dual GLP-1 and FGF21 Receptor Agonist in Healthy and Obese Chinese Subjects [0.03%]
HEC88473（一种新型GLP-1和FGF21受体激动剂）在健康及超重中国受试者中的耐受性、药代动力学及药效学首次人体单次递增剂量研究
Hong Zhang,Qianqian Li,Hong Chen et al.
Hong Zhang et al.
Background: HEC88473 is a novel long-acting dual agonist of glucagon-like peptide 1 (GLP-1) and fibroblast growth factor 21 (FGF21) receptors. It is a Fc fusion protein containing a fibroblast growth factor 21 and a GLP-1...